AN2 Therapeutics (ANTX) Income from Continuing Operations (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Income from Continuing Operations of 17349000.0 for Q1 2026, down 55.71% year-over-year from 39169717.93 in Q1 2025, and down 99.07% quarter-over-quarter from 8715000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Income from Continuing Operations for 6 consecutive years, with 17349000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 55.71% year-over-year to 17349000.0; the TTM figure through Mar 2026 stood at 42384000.0 (up 9.63% YoY), while the FY2025 annual figure was 35345000.0, up 67.7% from the prior year.
- Income from Continuing Operations eased to 17349000.0 in Q1 2026 per ANTX's latest filing, from 8715000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6595000.0 in Q2 2025 and bottomed at 60633000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 19333705.88 across 5 years, with a median of 14984000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 991.8% — and 2024, when it jumped 87.05%.
- AN2 Therapeutics' Income from Continuing Operations stood at 11866000.0 in 2022, then plunged by 410.98% to 60633000.0 in 2023, then soared by 87.05% to 7852000.0 in 2024, then declined by 10.99% to 8715000.0 in 2025, then sank by 99.07% to 17349000.0 in 2026.
- Business Quant data shows ANTX's Income from Continuing Operations at 17349000.0 in Q1 2026, 8715000.0 in Q4 2025, and 9725000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AN2 Therapeutics | 226.04 Mn | 226.04 Mn | - | -20.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.86 Mn |
| Mar 31, 2026 | -17.35 Mn |
| Dec 31, 2025 | -8.72 Mn |
| Sep 30, 2025 | -9.73 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -11.14 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Sep 30, 2024 | -12.92 Mn |
| Jun 30, 2024 | -14.98 Mn |
| Mar 31, 2024 | -17.62 Mn |
| Dec 31, 2023 | -60.63 Mn |
| Sep 30, 2023 | -39.59 Mn |
| Jun 30, 2023 | -21.38 Mn |
| Mar 31, 2023 | -22.34 Mn |
| Dec 31, 2022 | -11.87 Mn |
| Sep 30, 2022 | -30.22 Mn |
| Jun 30, 2022 | -13.39 Mn |
| Mar 31, 2022 | -22.36 Mn |
| Dec 31, 2021 | -7.62 Mn |
| Sep 30, 2021 | -6.91 Mn |